Leukemia and Myeloproliferative Disorders

Show Only Open Trials
1.

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

  • Study Status: Open to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
  • Protocol ID: MPD-RC 111
2.

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

  • Study Status: Open to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Polycythemia Vera (PV)
3.

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
4.

Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
5.

A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Plexxikon
6.

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML) with Core Binding Factor Abnormaility
  • Protocol ID: CALGB 10801
7.

CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: FLT3 Mutated Acute Myeloid Leukemia
8.

CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Acute Myeloid Leukemia
9.

NCI 8977: Phase 2 Trial of R11577 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

  • Study Status: Open to Enrollment
  • Sponsor: National Cancer Institute
  • Disease Status and/or Stage: Acute Myeloid Leukemia
10.

A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics, Inc.
11.

CALGB 10404: A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Chronic Lymphocytic Leukemia (CLL)
12.

A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Tragara Pharmaceuticals
  • Disease Status and/or Stage: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or High-risk Myelodysplasia (MDS)
13.

Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematological Malignancies
14.

A Phase I/II Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)

  • Study Status: Open to Enrollment
  • Sponsor: New York Cancer Consortium; National Cancer Institute
  • Disease Status and/or Stage: Myelodysplastic Syndromes (MDS); Acute Myeloid Leukemia
15.

A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)

  • Study Status: Open to Enrollment
  • Sponsor: Sunesis Pharmaceuticals
  • Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
16.

Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine

  • Study Status: Open to Enrollment
  • Sponsor: Onconova Therapeutics, Inc
  • Disease Status and/or Stage: Myelodysplastic Syndromes (MDS) Including RAEB and Chronic Myelomonocytic Leukemia (CMML)
17.

CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB; NCI; Eastern Cooperative Oncology Group; Southwest Oncology Group
  • Disease Status and/or Stage: Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
  • Protocol ID: CALGB 10403
18.

A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence

  • Study Status: Open to Enrollment
  • Sponsor: Celgene Corporation
  • Disease Status and/or Stage: Primary Myelofibrosis
19.

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia

  • Study Status: Open to Enrollment
  • Sponsor: Clavis Pharma
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML)
20.

MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

  • Study Status: Closed to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: Polycythemia Vera (PV)
21.

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS)

  • Study Status: Closed to Enrollment
  • Disease Status and/or Stage: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
22.

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies

  • Study Status: Closed to Enrollment
  • Sponsor: Calistoga Pharmaceuticals
  • Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
Top of page